Plus Therapeutics Inc - Asset Resilience Ratio
Plus Therapeutics Inc (PSTV) has an Asset Resilience Ratio of 60.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Plus Therapeutics Inc's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Plus Therapeutics Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Plus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Plus Therapeutics Inc (PSTV) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.09 Million | 60.72% |
| Total Liquid Assets | $12.09 Million | 60.72% |
Asset Resilience Insights
- Very High Liquidity: Plus Therapeutics Inc maintains exceptional liquid asset reserves at 60.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Plus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Plus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Plus Therapeutics Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Plus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.68% | $4.36 Million | $16.32 Million | -26.54pp |
| 2024-12-31 | 53.22% | $3.53 Million | $6.63 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $11.39 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $23.99 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $31.61 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $34.61 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $37.70 Million | -- |
| 2006-12-31 | 15.99% | $3.98 Million | $24.87 Million | -11.84pp |
| 2005-12-31 | 27.83% | $7.84 Million | $28.17 Million | -13.71pp |
| 2004-12-31 | 41.54% | $10.58 Million | $25.47 Million | +0.78pp |
| 2003-12-31 | 40.76% | $11.45 Million | $28.09 Million | -9.79pp |
| 2002-12-31 | 50.55% | $19.88 Million | $39.32 Million | -21.89pp |
| 2001-12-31 | 72.44% | $31.25 Million | $43.14 Million | +1.63pp |
| 2000-12-31 | 70.80% | $37.01 Million | $52.27 Million | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more